靶向溴结构域和超末端基序家族蛋白的蛋白靶向嵌合分子对多发性骨髓瘤临床前模型具有活性
本研究在骨髓瘤临床前模型中评估靶向BRD4及其他BET家族蛋白的蛋白靶向嵌合分子(PROTACs),发现其以时间和浓度依赖方式降低骨髓瘤细胞系活力,诱导G0/G1期阻滞、CDK4/6降低、p21升高和凋亡;可克服硼替佐米、地塞米松、来那度胺和泊马度胺耐药,在TP53野生型或缺失的等基因骨髓瘤细胞中活性维持;与地塞米松、BH3模拟物和Akt通路抑制剂协同;诱导患者原代细胞活力快速丧失并延缓MM1.S异种移植瘤生长。
要点
- BET特异性PROTACs以时间和浓度依赖方式降低骨髓瘤细胞系活力。
- PROTACs克服硼替佐米、地塞米松、来那度胺和泊马度胺耐药。
- 与地塞米松、BH3模拟物和Akt通路抑制剂显示协同作用。
核心结论
- BET降解剂对多发性骨髓瘤临床前模型显示出有前景的活性,支持其向复发和/或难治性疾病患者的临床转化。
研究设计与样本
- 在骨髓瘤模型中进行临床前研究,使用靶向BRD4及其他BET家族成员以进行泛素化和蛋白酶体降解的双功能蛋白靶向嵌合分子(PROTACs)。
主要发现
- PROTACs以时间和浓度依赖方式强效降低骨髓瘤细胞系活力,伴随G0/G1期阻滞、CDK4和CDK6水平降低、p21水平升高及凋亡诱导。
- 这些药物特异性降低下游BRD4靶点(包括c-MYC和N-MYC)的细胞水平,一种靶向Cereblon的PROTAC显示出与免疫调节剂相似的下游效应。
- PROTACs克服硼替佐米、地塞米松、来那度胺和泊马度胺耐药,其活性在TP53野生型或缺失的等基因骨髓瘤细胞中维持。
- 联合研究显示与地塞米松、BH3模拟物和Akt通路抑制剂协同相互作用。
- BET特异性PROTACs诱导骨髓瘤患者原代细胞活力快速丧失,并延缓MM1.S异种移植瘤生长。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bromodomain and extraterminal (BET) domain containing protein (BRD)-4 modulates the expression of oncogenes such as c-myc, and is a promising therapeutic target in diverse cancer types. We performed pre-clinical studies in myeloma models with bi-functional protein-targeting chimeric molecules (PROTACs) which target BRD4 and other BET family members for ubiquitination and proteasomal degradation. PROTACs potently reduced the viability of myeloma cell lines in a time-dependent and concentration-dependent manner associated with G0/G1 arrest, reduced levels of CDKs 4 and 6, increased p21 levels, and induction of apoptosis. These agents specifically decreased cellular levels of downstream BRD4 targets, including c-MYC and N-MYC, and a Cereblon-targeting PROTAC showed downstream effects similar to those of an immunomodulatory agent. Notably, PROTACs overcame bortezomib, dexamethasone, lenalidomide, and pomalidomide resistance, and their activity was maintained in otherwise isogenic myeloma cells with wild-type or deleted TP53. Combination studies showed synergistic interactions with dexamethasone, BH3 mimetics, and Akt pathway inhibitors. BET-specific PROTACs induced a rapid loss of viability of primary cells from myeloma patients, and delayed growth of MM1.S-based xenografts. Our data demonstrate that BET degraders have promising activity against pre-clinical models of multiple myeloma, and support their translation to the clinic for patients with relapsed and/or refractory disease.
引用
- Zhang X, Lee HC, Shirazi F, et al. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia. 2018. PMID: 29581547. doi:10.1038/s41375-018-0044-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。